DUBLIN, September 29, 2016 /PRNewswire/ --
DS Biopharma (DS) will today present data on their Phase IIa study with DS107 for the treatment of atopic dermatitis at the 25th European Academy of Dermatology and Venereology in Vienna, Austria.
The presentation is entitled “DS107 Clinical Data: A novel oral treatment for moderate to severe atopic dermatitis in adults” and will take place in Hall N between 13.15 and 14.45 local time.
DS is planning to initiate an Oral DS107 Phase IIb study in patients with moderate to severe atopic dermatitis later this year in the United States.
About DS Biopharma
DS Biopharma, headquartered in Dublin, Ireland, is a privately held drug discovery and development company working on new medicines that improve the quality of life for people with diseases for which existing therapies are ineffective or unsafe. DS has developed a proprietary bioactive lipid technology platform. In addition to Oral DS107, the Company is developing Topical DS107 for mild to moderate atopic dermatitis which will begin recruitment for a Phase IIb study later this year and DS109, for the treatment of inflammatory skin disorders which is also due to enter the clinic next month.
SOURCE DS Biopharma
